Clinical Testing News and Research

RSS

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

Curis, Inc. announced today that its licensee Debiopharm S.A. has treated the first patient in a Phase I clinical trial for small molecule heat shock protein 90 (Hsp90) inhibitor Debio 0932, formerly called CUDC-305.

27 Apr 2010

GORE VIABIL Biliary Endoprosthesis receives European CE Mark approval for expanded indication

W. L. Gore & Associates (Gore) today announced it has received European CE Mark approval for an expanded indication of the GORE® VIABIL® Biliary Endoprosthesis that allows removal of the device up to 12 months after implantation for the treatment of benign or malignant biliary strictures. The GORE® VIABIL® Biliary Endoprosthesis first received CE Mark approval in December 1999 and U.S. Food and Drug Administration (FDA) approval in January 2002 for the treatment of biliary strictures due to malignant neoplasms.

27 Apr 2010

OICR makes equity investments in three promising Ontario technologies

Frank Stonebanks, Vice-President, Commercialization and Chief Commercial Officer of the Ontario Institute for Cancer Research today announced that OICR has made equity investments in three promising Ontario technologies to accelerate their commercialization.

26 Apr 2010

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the corresponding phase I study. The company is active in several disease areas and is currently developing a total of twelve prospective products in all stages of the development pipeline up to clinical phase II.

24 Apr 2010

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Biomagnetics Diagnostics Corp., a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, today announced it has received important commitments from two leading research laboratories in India for clinical validation testing for malaria and tuberculosis (TB) detection and diagnosis.

21 Apr 2010

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has established an action plan for obtaining cost reimbursement coverage for Generex Oal-lyn™, including the development of an insurance product that covers the costs of Generex Oral-lyn™ and any additional and/or comparable diabetes products.

19 Apr 2010

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases of the NIH in the form of a Phase II Small Business Innovation Research Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax.

19 Apr 2010

NIH awards Corgenix Medical $600,000 grant to develop diagnostic tests for Ebola and Marburg virus

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, including innovative products for emerging pathogens and lethal viruses, today announced a major extension of the collaborative effort to combat important viral diseases.

15 Apr 2010

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that eight presentations reporting on the Company's progress in diverse cancer therapy product candidates will be given at the 101st Annual Meeting of the American Association for Cancer Research, April 17 – 21, 2010, in Washington, DC.

13 Apr 2010

Idaho man fourth in country to receive Levacor- VAD implant

After receiving only the fourth U.S. implant of a new-generation, Utah-made ventricular assist (VAD ) device, an Idaho man with heart failure is looking forward to resuming an active life following an operation on March 17 at University of Utah Hospital.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Angiotech Pharmaceuticals, Inc., a specialty pharmaceutical and medical device company, today announced the closing of its acquisition of certain product candidates and technology assets of Haemacure Corporation. Haemacure has been involved in proceedings under Canada's Bankruptcy and Insolvency Act and Chapter 11 of the United States Bankruptcy Code.

8 Apr 2010

Clinical testing service for safer dosing of warfarin

Machaon Diagnostics, California's only independent laboratory for testing bleeding and clotting disorders has launched a clinical testing service for patients that have been prescribed warfarin. Warfarin, also known as Coumadin, Jantoven or warfarin sodium, is a potent 'blood thinner' or anticoagulant.

8 Apr 2010

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury.

8 Apr 2010

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

Kinetic Muscles Inc., a leading innovator of neurorehabilitation technology, announced it has received a 2-year Phase II SBIR grant to study a new treatment for veterans returning from active duty with traumatic brain injury.

5 Apr 2010

DNA patent case: US District Judge rules in favor of AMP

The Association for Molecular Pathology (AMP) is an international medical and professional association representing approximately 1,800 physicians, doctoral scientists, and medical laboratory scientists who perform laboratory testing based on knowledge derived from molecular biology, genetics, and genomics. AMP applauds US District Judge Robert Sweet's ruling in favor of the plaintiffs in the lawsuit, Association for Molecular Pathology, et al. v. U.S. Patent and Trademark Office, et al.

2 Apr 2010

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

AGA Medical gets IDE approval to evaluate AMPLATZER Cardiac Plug

AGA Medical Holdings, Inc. today announced it has received conditional Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration to evaluate the safety and efficacy of its AMPLATZER® Cardiac Plug, or ACP, to close the left atrial appendage.

25 Mar 2010

Evotec AG reports financial results and corporate updates for 2009

Based on the Action Plan 2012, Evotec decided in March 2009 to strengthen its discovery alliances, creating the central vehicle for growth, and to implement strict cost cutting and restructuring measures. The Company reduced headcount in administrative and clinical development functions, reprioritised its R&D activities, concentrated its operations in Europe and closed the former facility of Renovis, Inc. in South San Francisco.

25 Mar 2010

Regado Biosciences announces first successful subcutaneous application of an aptamer

Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia.

15 Mar 2010

Clinical Testing News and Research

Debiopharm commences treatment in Phase I clinical trial for Debio 0932 small molecule Hsp90 inhibitor

GORE VIABIL Biliary Endoprosthesis receives European CE Mark approval for expanded indication

OICR makes equity investments in three promising Ontario technologies

AFFiRiS' AD02 Alzheimer's vaccine candidate in phase II clinical testing

Biomagnetics Diagnostics receives commitment for clinical validation testing in India for malaria, TB diagnosis

Generex Biotechnology announces plan to obtain cost reimbursement coverage for Generex Oal-lyn

Protein Potential receives Phase II SBIR Grant to develop vaccine for prevention of P. vivax infections

NIH awards Corgenix Medical $600,000 grant to develop diagnostic tests for Ebola and Marburg virus

Immunomedics' progress in cancer therapy product candidates to be presented at AACR 2010

Idaho man fourth in country to receive Levacor- VAD implant

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Angiotech Pharmaceuticals acquires manufacturing, intellectual property rights from Haemacure

Clinical testing service for safer dosing of warfarin

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

KMI receives 2-year Phase II SBIR grant to study new treatment for TBI

DNA patent case: US District Judge rules in favor of AMP

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

AGA Medical gets IDE approval to evaluate AMPLATZER Cardiac Plug

Evotec AG reports financial results and corporate updates for 2009

Regado Biosciences announces first successful subcutaneous application of an aptamer

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News